Amanote Research
Register
Sign In
A Brain-Penetrant MET Inhibitor Achieves Responses in Glioblastoma
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2018-186
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
October 26, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
A Brain Penetrant Mutant IDH1 Inhibitor Provides in Vivo Survival Benefit
Scientific Reports
Multidisciplinary
The Brain-Penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models
Science advances
Multidisciplinary
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
Cell
Biochemistry
Genetics
Molecular Biology
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
Fatal Measles Virus Infection Prevented by Brain-Penetrant Fusion Inhibitors
Journal of Virology
Insect Science
Immunology
Microbiology
Virology
Nivolumab Plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors
Cancer Discovery
Oncology
An Orally Bioavailable C-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Anti-Cancer Agents in Medicinal Chemistry
Cancer Research
Molecular Medicine
Pharmacology
A Novel One-Armed Anti-C-Met Antibody Inhibits Glioblastoma Growth in Vivo
Clinical Cancer Research
Cancer Research
Oncology
